Psychedelic Spotlight News

New Players, New Studies & Financial Results [MindMed, CMPS, NUMI, TRUFF & WESA]

Researchers personally trying MDMA, a new company on the block, financial results for MindMed (MMED / MNMD / MMQ) & Compass Pathways (CMPS) & news on Numinus Wellness (NUMI) & Red Lights Holland (TRIP/TRUFF), this is what we will be covering in today’s episode. Timestamps: 0:00 - Intro 0:18 - FDA clears researchers to test MDMA on themselves 1:55 - MindMed (MMED / MNMD) announces Q1 Financials 4:30 - Compass Pathways (CMPS) announces Q1 Financials 6:56 - Numinus Wellness (NUMI) supplies psilocybin extract to Optimi Health 8:17 - Red Light Holland (TRIP / TRUFF) has a new app called ‘iMicro’ 9:31 - Wesana Health Holdings (WESA) begins trading on the CSE Link to the FDA clearing researchers to test MDMA on themselves: https://www.marijuanamoment.net/fda-clears-researchers-to-study-mdma-use-by-therapists-being-trained-in-psychedelic-medicine/ Link to Mindmed’s Q1 2021 Financial report and business highlights: https://www.newswire.ca/news-releases/mindmed-announces-2021-q1-financial-results-cash-balance-of-160m-usd-194m-cad-to-execute-on-diverse-clinical-pipeline-816112809.html Link to Compass Pathways (CMPS) Q1 Financial report:https://www.globenewswire.com/news-release/2021/05/13/2228969/0/en/COMPASS-Pathways-plc-announces-financial-results-and-business-highlights-for-the-first-quarter-2021.html Link to Numinus (NUMI) supplying psilocybin extract to Optimi Health: https://psilocybinalpha.com/news/numinus-wellness-and-optimi-health-submit-all-natural-psilocybin-extract-to-health-canada-for-pre-clinical-trial-application Link to Red Light Holland’s (TRIP / TRUFF) new app ‘iMicro’: https://investingnews.com/news/agriculture-investing/red-light-holland-imicro-digital-care-app-and-telecounseling-goes-live/ Link to Wesana Health Holdings (WESA): https://psilocybinalpha.com/news/wesana-health-commences-trading-on-the-cse Image source: https://www.google.com/search?q=mike+tyson&rlz=1C1CHBF_enCA821CA821&sxsrf=ALeKk01FAUv0g0uK0yvLRLlkKOCgPEda6g:1621187634437&source=lnms&tbm=isch&sa=X&ved=2ahUKEwiagcLI4s7wAhWSF1kFHUeECgsQ_AUoAnoECAEQBA&biw=1600&bih=699#imgrc=Hwv5W22HvZQ3QM Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news! Follow us on social media! 🙌 Instagram: @psychedelicinvestor Email: thepsychedelicinvestor@gmail.com Facebook: @thepsychedelicinvestor editing by: @themyaholy Music: www.bensound.com https://benzinga.grsm.io/jameshallifax1834 https://benzinga.grsm.io/thepsychedelicinvestor DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change. #MindMed #PsychedelicStocks #CMPS

The Essence Institute Explores Psilocybin Truffle Medicine In the Netherlands

Culture, Treatment

In the heart of the Netherlands, legal psilocybin truffle retreats help seekers explore the benefits of psychedelics at the Essence Institute.

How Clinical Trials Work and Who is WINNING the Race (FOR NOW) // MAPS, CMPS, MNMD & more

Videos

Who's winning the psychedelics race and how do clinical trials work? This topic has been requested a lot lately so we decided to give you a rundown on the clinical trials system and the psychedelic-inspired companies who are furthest advanced at the moment. Of course, for now, MAPS is leading the race. However, other public companies such as Compass Pathways (CMPS) and MindMed (MMED / MNMD) are not far behind, for now. Hopefully, this introductory video will help some new retail investors who are considering investing in biotech companies who do not te have an approved drug, to understand the importance that clinical trials need to play in their investing decisions. Timestamps: 0:00 - Intro 1:34 - What is the clinical trial system? 2:15 - Preclinical 3:00 - Phase 0 3:32 - Phase I 5:45 - Phase II 8:26 - Phase III 10:28 - Phase IV 11:08 - Who's winning the race? 11:16 - MAPS ( non-for-profit entity): Has already completed a Phase III study on MDMA to treat PTSD 12:02 - Compass Pathways (CMPS) has a Phase IIb trial to treat TRD with COMP360 12:28 - MindMed (MMED / MNMD) has completed a Phase IIa LSD study to treat Anxiety and will begin phase IIb this year. MindMed also has other Phase II studies involving LSD & Ibogaine (18-MC) 13:23 - Mydecine (MYCO) and CYBIN (CYBN) following suit Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news! Follow us on social media! 🙌 Instagram: @psychedelicinvestor Email: thepsychedelicinvestor@gmail.com Facebook: @thepsychedelicinvestor editing by: @themyaholy Music: www.bensound.com https://benzinga.grsm.io/jameshallifax1834 https://benzinga.grsm.io/thepsychedelicinvestor DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change. #MindMed #Numi #CMPS